Boehringer Plans to Expand Outreach of Blood Thinner to China this Year Despite Pradaxa Lawsuits
Cerebral hemorrhaging, gastrointestinal bleeding, death—even though these frightening side effects have been named in a growing number of Pradaxa lawsuits, it was reported in April that the blood thinner’s manufacturer plans to expand its reach into foreign markets this year.
According to a recent report from The Global Mail, Boehringer-Ingelheim will facilitate educational events on stroke prevention this year to more than 4,000 cardiologists in China, which houses the world’s biggest market. The article published April 24th, 2013 indicates the company’s efforts to sell Pradaxa will be aided by the American College of Cardiology.
That last bit may come as a surprise to the medical community considering the fact that the medication, prescribed to prevent strokes in patients with non-valvular atrial fibrillation, has been linked to more than 500 deaths, according to adverse event reports filed with the U.S. Food and Drug Administration (FDA). Since it was approved in 2000, the drug has also been named in a growing number of Pradaxa lawsuits.
Pradaxa Lawsuits Continue to Be Filed in Federal Litigation
More than 600 claims were pending in a federal Pradaxa litigation (MDL) underway in U.S. District Court, Southern District of Illinois as of May 2013, court records indicate.
But perhaps most importantly, the glaring issue Boehringer-Ingelheim fails to address involves the irreversibility of Pradaxa side effects. Not only do they seem to be widespread, they are also life-threatening since doctors are often unable to stop the internal bleeding in patients once it begins. The blood thinner is currently being prescribed in more than 90 countries and has generated more than 1 billion in U.S. sales, the drugmaker told The Global Mail.
Pradaxa has been linked to the following life-threatening side effects: • Cerebral hemorrhage – Pradaxa bleeding in the brain. • Severe Pradaxa internal bleeding following a minor trauma, such as a fall. • Gastrointestinal (stomach) bleeding. • Death from serious Pradaxa internal bleeding.
A Mar.5, 2013 article published by Medicalxpress.com said that scientists at Portola Therapeutics in San Francisco have created a recombinant protein that can reverse the effects of two other anticoagulants, Eliquis (apixaban) and Xarelto (rivaroxaban), that utilize factor Xa inhibitors to prevent blood clotting, but not Pradaxa.
The report states that Boehringer was in its first phase of developing its own antidote for Pradaxa, which had been named in 932 FDA reports of serious adverse events as of March 2011. These side effect reports included 120 deaths and 500 reports of severe bleeding, according to the agency.
How to File a Pradaxa Lawsuit
If you or a loved one experienced the life-threatening complications associated with Pradaxa, you may be eligible to file a claim against the manufacturer. To file a lawsuit alleging Pradaxa side effects, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414.